Psoriasis breakthrough? single shot may keep skin clear for over a year
NCT ID NCT04630652
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 24 adults with moderate-to-severe plaque psoriasis to understand how a single injection of risankizumab (Skyrizi) changes immune cells in the skin. The goal was to learn why some patients stay clear of psoriasis for up to 66 weeks without further treatment. Researchers took skin biopsies before and after the drug to track immune cell changes and build models that might predict who can achieve long-term remission.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Rockefeller Univesity
New York, New York, 10065, United States
-
University of California Davis Medical Center
Sacramento, California, 95817, United States
-
VA Northern California Health Care System
Sacramento, California, 95655, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new gel calm psoriasis Flare-Ups?
- Can a Once-Daily cream tame psoriasis in toddlers?
- Can a switch to guselkumab clear stubborn psoriasis?
- Can a new biologic clear stubborn psoriasis?
- Diet and exercise may tame psoriasis in kids — a trial puts it to the test
- Ancient herbal mix put to the test against psoriasis